Shedding of ctDNA, radiomics assessment of tumor disease volume (TDV), and concordance of mutations (mut) in synchronous liquid and tumor biopsies in metastatic breast cancer (MBC).

被引：0

作者：

Papakonstantinou, Andri

Gonzalez-Medina, Alberto

Matito, Judit

Ligero, Marta

Ruiz-Pace, Fiorella

Sunol, Anna

Rivero, Joaquin

Fasani, Roberta

Cruellas, Mara

Peg, Vicente

Borrell, Maria

Pimentel, Isabel

Munoz, Santiago Escriva De Romani

Gelpi, Judith Balmana

Nuciforo, Paolo

Dienstmann, Rodrigo

Saura, Cristina

Perez-Lopez, Raquel

Oliveira, Mafalda

Vivancos, Ana

机构：

[1] Karolinska Inst & Breast Canc Grp, Vall Hebron Inst Oncol VHIO, Dept Oncol Pathol, Barcelona, Spain

[2] Vall Hebron Inst Oncol VHIO, Canc Genom Grp, Barcelona, Spain

[3] Vall Hebron Inst Oncol VHIO, Radi Grp, Barcelona, Spain

[4] Vall Hebron Inst Oncol VHIO, Oncol Data Sci ODysSey Grp, Barcelona, Spain

[5] Vall Hebron Inst Oncol VHIO, Breast Canc Grp, Barcelona, Spain

[6] Vall dHebron Univ Hosp, Breast Canc Ctr, Breast Surg Unit, Barcelona, Spain

[7] Vall Hebron Inst Oncol VHIO, Mol Oncol Grp, Barcelona, Spain

[8] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept & Breast Canc Grp, Barcelona, Spain

[9] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain

[10] Vall dHebron Inst Oncol, Clin Canc Genet & Breast Canc Grp, Barcelona, Spain

[11] Vall Hebron Inst Oncol, Barcelona, Spain

[12] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1086

引用

页数：1

共 50 条

[31] ASO Author Reflections: Advancing Circulating Tumor Cells as Liquid Biopsies to Efficiently Target Metastatic Breast Cancer
Alexander Ring
Julie E. Lang
Annals of Surgical Oncology, 2022, 29 : 2895 - 2896
[32] Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study
Kagawa, Yoshinori
Elez, Elena
Garcia-Foncillas, Jesus
Bando, Hideaki
Taniguchi, Hiroya
Vivancos, Ana
Akagi, Kiwamu
Garcia, Ariadna
Denda, Tadamichi
Ros, Javier
Nishina, Tomohiro
Baraibar, Iosune
Komatsu, Yoshito
Ciardiello, Davide
Oki, Eiji
Kudo, Toshihiro
Kato, Takeshi
Yamanaka, Takeharu
Tabernero, Josep
Yoshino, Takayuki
CLINICAL CANCER RESEARCH, 2021, 27 (09) : 2515 - 2522
[33] PIK3CA MUTATIONS AND LOSS OF PTEN EXPRESSION IN CIRCULATING TUMOR CELLS (CTCS) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC)
Lozano Mejorada, R.
Matos, I.
Marcos, R. A.
Alfonso, S.
Guillen, C.
Noguerido, A.
Rua, O.
Vidal, R.
Hernandez, M. A.
Garcia, J. L.
Gomez Bernal, A.
Rodriguez, C. A.
Cruz Hernandez, J. J.
ANNALS OF ONCOLOGY, 2014, 25
[34] Detection of activating estrogen receptor 1 (ESR1) in circulating tumor DNA (ctDNA) in hormone-receptor positive metastatic breast cancer (MBC)
Austin, L.
Rodriguez, A.
Jaslow, R.
Fortina, P.
Nagy, R.
Zill, O.
Talasaz, A.
Cristofanilli, M.
CANCER RESEARCH, 2016, 76
[35] Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient
Welter, Lisa
Xu, Liya
McKinley, Dillon
Dago, Angel E.
Prabakar, Rishvanth K.
Restrepo-Vassalli, Sara
Xu, Kevin
Rodriguez-Lee, Mariam
Kolatkar, Anand
Nevarez, Rafael
Ruiz, Carmen
Nieva, Jorge
Kuhn, Peter
Hicks, James
COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2020, 6 (06):
[36] Fragmentomic analysis of a circulating tumor DNA targeted cancer gene panel discriminates ER status in metastatic breast cancer liquid biopsies
Helzer, Kyle
Sperger, Jamie
Shi, Yue
Carreno, Viridiana
Krause, Hannah
Kaufmann, Katherine
Mora-Rodriguez, Leilani
Bootsma, Matthew
Burkard, Mark
O'Regan, Ruth
Wisinski, Kari
Lang, Joshua
Zhao, Shuang
West, Malinda
Sharifi, Marina
CANCER RESEARCH, 2024, 84 (09)
[37] Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC)
Vidula, Neelima
Juric, Dejan
Niemierko, Andrzej
Spring, Laura
Moy, Beverly
Malvarosa, Giuliana
Yuen, Megan
Habin, Karleen R.
Shin, Jennifer Adrienne
Peppercorn, Jeffrey M.
Isakoff, Steven J.
Ellisen, Leif W.
Iafrate, A. John
Bardia, Aditya
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[38] Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.
Giordano, A.
Giuliano, M.
Hsu, L.
Handy, B. C.
Ueno, N. T.
Andreopoulou, E.
Alvarez, R. H.
Valero, V.
Hortobagyi, G. N.
Cristofanilli, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[39] The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of "indolent" stage IV disease (Stage IVindolent)
Davis, Andrew A.
Pierga, Jean-Yves
Dirix, Luc Yves
Michiels, Stefan
Rademaker, Alfred
Reuben, James M.
Fehm, Tanja N.
Munzone, Elisabetta
Giuliano, Mario
Vidal-Martinez, Jose
Mavroudis, Dimitrios
Grisanti, Salvatore
Generali, Daniele Giulio
Garcia-Saenz, Jose Angel
Stebbing, Justin
Dawson, Sarah-Jane
Gazzaniga, Paola
Bidard, Francois-Clement
Cristofanilli, Massimo
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[40] PRIMARY TUMOR IN BREAST CANCER (BC) AND PHENOTYPE IN POSITIVE LYMPHNODES AND LATER DISEASE RECURRENCE (METASTATIC BREAST CANCER, MBC): RESULTS OF THE PRIMET-TRIAL (WSG/DETECT)
Wuerstlein, Rachel
Liedtke, Cornelia
Gluz, Oleg
Heitz, Florian
Kates, Ronald
Fehm, Tanja
Nitz, Ulrike
Harbeck, Nadia
BREAST, 2011, 20 : S22 - S23

← 1 2 3 4 5 →